Background: Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide with estimated incidence rate of 43, 1 per 100,000 and also in Argentine. With an estimated incidence rate of 71, 2 per 100,000 in 2012 our country is among the two ones with the high incidence in all Latin-America where the estimated incidence rate for BC is 47, 2 per 100,000.
Introduction
Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide with an estimated age-standardized rate (ASR) incidence, all ages, of 43, 1 per 100,000 according to the data from Globocan 2012 [1] . According to the same source of data the incidence of BC rates vary between the different geographic regions. Thus we have rates ranging from 29, 1 per 100,000 in Asia and 36,2 per 100,000 in Africa to 80,3 per 100,000 within the European Union and 85,8 per 100,000 in Australia / New Zealand; furthermore, there is wide variation in incidence rates of BC within the regions mentioned. The incidence of BC in America has two clearly defined situations. The northern region of the continent, Canada and USA, show incidence rates of 79, 8 per 100,000 and 92,9 per 100,000 respectively. The rest of the continent has been added for their study under the name Latin America / Caribbean, with an incidence rate for BC of 47,2 per 100,000. Within this region there are differences in the incidence rates among the Caribbean area with 46, 1 per 100,000, Central America with 32,8 per 100,000 and South America with 52,1 per 100,000 [1, 2] . Incidence rates for BC increased in all Latin America countries for the period 1980-2010 [3] .
According to the World Bank [4] , Argentina, situated in South America, belongs both to the "Less developed regions" and to the "Medium human development" group of countries where BC's estimated incidences are of 31, 3 x100, 000 and 26, 5x100, 000 respectively [1] . Despite these two categories and its geographic location Argentina is strikingly present among the countries with a high incidence rate for BC (71, 2 per 100,000). This incidence rate is near 1, 4 fold higher considering its geographical location and between 2, 3 and 2, 7 fold higher when considering their levels of development. The average incidence rate of BC in the five bordering countries is 45, 4 per 100,000 (range, 19, 2-69, 8), 1,5 fold lower than the one indicated for Argentina [1] . Demographic, hereditary, economic, cultural, environmental, and lifestyle risk factors may account for this high BC incidence rate.
The Collaborative Group studied during the years 2012-2013 newly diagnosed female BC in Argentina to describe in detail the clinical and epidemiological characteristics of this cancer in an attempt to explain the high incidence rates observed above all estimated rates for this country.
Material and methods
The "Collaborative Group for the Study of Female Breast Cancer in Argentine" (PROYCAM 2012 ) is a multi-center prospective cohort study specifically designed to investigate the features of the breast cancer in Argentine women.
The present study was conducted between 1 January 2012 and 31 December 2013. A consortium of 64 physicians from 75, public (26) and private (49) , health services reported 1732 case patients. Case definition was female cases of BC with a histologically confirmed laboratory diagnosis. Techniques and instruments of data collection: data were collected in two structured forms that appear in the on-line system (www.cancerdemama2012.org.ar). The first (Figure 1 ), self-administered character, is filled by the patient where she reports on age at diagnosis, level of education, health coverage, body mass index (BMI), menstrual history [age at menarche and menopause, exogenous hormone consumption and years of usage: OC and hormone replacement therapy (HRT)], reproductive history: number of full-term pregnancies, age at first full-term pregnancy, abortions, breastfeeding (practice and duration); the following information was also requested: personal non-cancer and cancer breast pathology history, a family history of breast cancer (limited to first and second-degree relatives only) and non-breast cancer. The second (Figure 2) , an online form, was completed by the physician who reported the following data: clinical characteristics of tumor (localization, size), nodal involvement (presence, localization and number), distal metastasis (presence and site) and TNM clinical staging following Breast Cancer Staging, AJCC [5] . Data on histological types following the WHO Classification of Tumours of the Breast [6] and grade diagnosis, hormonal receptors status, Her2-neu overexpression, ki 67 and CK-5-6 immunohistochemistry studies, sentinel node study and pathological TNM were also collected. Diagnostic methods employed were also recorded. Population data was obtained from the National Office of Population Census (INDEC) [7] . Information and ethical considerations repairs: the project includes the principles contained in the Declaration of Helsinki, the National Law 25326 of Habeas Data Personal Data Protection and the National Patient Rights Act 26529 in its relationship with the professionals and health institutions. All patients signed a written informed consent (Figure 3 ).
Results

Data collection
Our analysis included 1732 patients with newly histologically confirmed breast cancer diagnosed and reported during the years 2012 and 2013. Argentina comprises 24 administrative units, 23 provinces and the city of Buenos Aires, capital of the country, a unit separated from the province of Buenos Aires. Seventy-four physicians, from 75 regional health services, both public (26) and private (49) , reported throughout the country (18 provinces out of 24).
Demographic characteristics
Data on age of patients was available in 1710 cases (99, 2%). The average age is 59 years; the median, 59 years; the mode, 51 years; with a standard deviation of, 14 years and a range between a minimum of 23 years to a maximum of 92 years. The highest percentages of cases are concentrated in the age-group of 50-54 years (12, 3%). Uncommon below 30 years (1,1%), BC doubles the cases in 30-34 years old women (2,1%), keeping this rate of increase in group 35-39 years-olds (5,3%) and in the 40 to 44 age group (8,5%). Up until this age group the increase of cases is almost constant, every five-year periods; afterwards the trend tends to stabilize between the 45-49 and the 65-69 age groups. On considering the two ages taken as the lower age for mammography screening schemes, i.e. 40 and 50 years old [8, 9] , we have a total of 17.0% of patients under 40 and 27.1% of patients below the 50 years old. A 15, 9% of the patients are 74 years old or more at age of diagnosis (Table 1) .
As for of health coverage systems for patients (data available in 96, 7% of patients) union-organized health insurance prevails (60, 2%) with a lower incidence of uninsured patients (17, 6%) covered by the public health system. The subsectors of mutual health societies and private prepaid companies represent 2, 3% and 17, 6% of the cases, respectively ( Table 1) .
The education level, data available in 96,7% of the cases, shows that a relative significant number of cases has failed to complete their primary education (9,6%); adding full primary education (17,2%) and incomplete secondary education (13,1%) makes a total of 39,9% of patients. A total of 52, 2% of the patients have a high school degree or higher education; completed university studies were achieved by 24% of patients (Table 1) .
Gynecological and reproductive history
Age at menarche in patients, data available in 94,6% of patients, shows an average of 13 years, a median of 13 years, a mode of 13 years, a standard deviation of 2 years and a range from a minimum of 9 years to a maximum of 21 years. The group with the highest percentage (40, 6%) of cases corresponded to 13 and 14 years ( Table 2) .
The data about menstruation is available in 94, 6% of patients; 72, 3% of patients were menopausal at the time of diagnosis. The age of menopause has a median of 49 years (range 21-64) ( Table 2 ). Only 9, 5% of the studied women has a history of use of hormone replacement therapy (data available for 92, 4% of cases); length of use, in most cases (69, 1%), was from 1 to 5 years with a median of 3 (range 1-24) years (Table 2) . 
Menopausal status
Age at menarche (median, range) 13 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) Premenopausal status, n (%) 396 (22, 9) Postmenopausal status, n (%) 1752 (72,3)
Age at menopause (median, range) 49 Hormone replacement therapy (HRT) use (yes), n (%) 165 (9, 5) Duration of using the HRT (years) (median, range) 3 (1-24)
Reproductive history
Ever full-term pregnancy (yes), n (%) 1387 (80,9)
Age at first full-term pregnancy (median, range) 24 Age ≥30 years at first full-term pregnancy, n (%) 161 (11, 6) Time between menarche and first pregnancy (years) (median, range)
(0-33)
Number of full-term pregnancies, n (%) About 80, 9% of patients report having had a full-term pregnancy (a 100% of data available). The most frequent number of children (data available for a 96% of cases) is 2 children (35, 6%) followed by the group of 3 children with 26, 0%, ( Table 2 ). The age of women at birth of first child (a 93% of data available) shows an average of 24 years, median 24 years, a mode of 25 years, a standard deviation of 5 years and a range from a minimum of 14 years to a maximum of 46 years. The group with the highest percentage of children corresponds to 21-25 years old patients (34, 6%). A total of 11, 6% were primiparous patients older than 30 years (Table 2) . Time between menarche and first pregnancy shows a median of 12 (range: 0-33) years (Table 2 ). All patients with children (80.9%) reported having breastfed; the median duration of breastfeeding (a 76% of data available) for the total number of children was 6 months, range 1-24 months (Table  2) .Oral contraceptives were used by 37, 2% of patients with a median duration of 3 (range 2-6) years. Nulliparous women accounted for 19, 1% of the cases studied. History of abortion and the number of it (a data available for 80% of cases) was present 
Variables Patients
History of personal breast pathology, n (%) 535 (30.9)
Mammary dysplasia, n (%) 227 (13. 1)
Atypical hyperplasia and carcinoma "in situ", n (%) 36 (2.1) in 28.9% of the cases with 84, 6% of these cases for no more than two occasions (Table 2) .
Health history
The BMI was recorded in 89, 1% of cases; data showed a 39, 6 % of patients with overweight and 18.1% with obesity ( Table 2 ).
The diagnosis of benign breast conditions (dysplasia) (a data available 94, 3% of cases) was present in 13, 1% of cases. Conditions such as atypical hyperplasia and carcinoma "in situ" (data available for 93, .4% of cases) were present in 1, 7% of cases. A previous history of breast cancer in patients (a data for 94, 0% of cases) was present in of 9, 8% of cases (Table 3) .
A personal history of non-breast cancer is present in 57 cases (3, 3%); 56 patients with a family history in one location and one patient in two (cervical and colon and rectum). A history of a cervical cancer is the most common (29, 8%) followed by the colon and rectum (10, 5%). Other non-specified cancers (47, 4%) are grouped in the Other NOS (not otherwise specified) category (Table 3 ).
The 27, 9% of cases have a family history of breast cancer. As for family members affected aunt and cousin with 39, 0% of cases, followed by the mother in 36, 3% sister with 23, 4% of cases; in 9, 01% of cases this family history is associated to more than one of the members (Table 3) .
A family history of non-breast cancer is found in 23, 7% of cases. In order of frequency, there were 17,8% cases of lung cancer, 17, 6% cases of colorectal cancer and 14, 4% of prostate cancer ( Table  3 ). The family member affected involves, mainly, the father or mother with 57, 9% of cases; in 6, 3% of cases this family history is associated to more than one member (Table 3) .
Clinical characteristics
The tumor´s locations in the breast (100% of data available) show a slight predominance in the right breast and the upper outer quadrant. In 3, 1% patients the tumors are located in both breasts at the time of diagnosis (bilateral synchronous forms) ( Table 4) .
Tumor size (84, 7% of data available) shows an average of 2,79 cm; a median 2,00 cm; a standard deviation of 2,03 cm and ranges from a 0,01 to a maximum of 15,00 cm. A total of 43,4% of cases are between 1 and 3 cm long and 7,% cases were tumors smaller than 1 cm. It is noteworthy that there are 13, 3% of tumors of 5 cm or more at time of diagnosis (Table 4 ).
In 26, 9% of cases there was nodal involvement (93, 8% of data available); most of them (92, 4%) were the axillary nodes (Table 4) . About 2, 5% of patients had metastases at the time of clinical diagnosis (94, 5 % of data available). The distribution of metastases were in bone (32, 7%), lung (25, 5%), liver (21, 8%) and CNS (16%) ( Table 4) .
Clinical staging (94, 2% of data available) showed 9, 4 % of Stage 0. The most frequent stage was Stage I with 34,5% of cases followed by stage IIA with 26,1 % and from then onwards there are decreasing amounts in the other stages to reach 0,6 % in stage IIIC. In stage IV a peak of 2, 4 % of cases is observed (Table 4) .
Histological characteristics
In the histological diagnosis (91, 1 % of data available) invasive forms predominate (80,8%) over non-infiltrative ones (10, 9%). In both, noninvasive and invasive forms, prevail the subtypes of ductal origin with 97, 11% and 87%% of cases respectively (Table 5. ). The diagnosis of invasive ductal carcinoma variants shows that NOS subtype, alone or in combination with others, is the most frequent (55,6%). In lobular infiltrating carcinoma the classical variants are the most frequent (51, 8%). Histologic grade carcinomas Grade II predominates (54, 4%). (Table 5 ).
Hormone receptor (HR) status was determined by immunohistochemistry in 83, 1 % of all cases for estrogen and 86,3 % for progesterone; Her2-neu status was also available in 82, 4% of all cases. For cases with data available on ER, PR, and HER2 (1415 case patients), we defined five tumor subtypes with the following results : ER (+)/ PR (+)/ Her2-neu (-), 69,5% ; ER (-)/ PR (-)/ Her2-neu (+), 5, 9% ;ER (+)/ PR (+)/ Her2-neu (+) (Triple-positive), 7,5% ; ER (-)/ PR (-)/ Her2-neu (-)(Triplenegative), 10,0% and others 7,1% (Table 5) .
Pathologic staging (a 92, 8% of data available) showed 7, 2% of Stage 0 a percentage lower than in clinical stage 0 (9, 4%). As in clinical TNM in pathological TNM the most frequent stages were I and IIA with 34, 8% and 22, 3 % respectively with decreasing amounts in the others stages until the 2.0 % in stage IIIC. As in cTNM in stage IV a peak of 2, 9 % cases are observed (Table 5) .
Discussion
As it is the case in developed countries, BC is the most common female cancer in Argentina [1] . BC incidence and mortality have been increasing steadily in South America and especially in Argentina during the past 25-30 years [10, 11] . Argentina, together with Uruguay, one of the neighbor countries, constitutes a cluster of women with the highest incidence rates for BC, not only in South America but also in all of Latin America [1, 10] . These strikingly high incidence rates of BC in women in these two countries have already been identified as exceptional for the region 30 years ago [11] . Despite the fact that the World Bank indices ranks Argentina in the group of "less developed" countries and describes it as "medium human development" the incidence rates and mortality for women with BC are not consistent with those observed in countries with similar characteristics of development [4] ; in contrast, our rates are similar to that of most developed countries, with a striking similarity to certain countries in Europe [10] . Taking all this into account, we intended to study the presentation features of new BC cases in women of our country in order to describe the clinicalepidemiological characteristics of presentation and compare our results with those published in the literature for Latin American countries and for those extra-regional countries with incidence rates similar to ours in an attempt to explain the high incidence rates observed above all estimated rates for this country.
Argentina is a large country with an extension of over 2, 8 million square km. According to the 2010 census, the total population was 40,117,096 inhabitants. Its population is mainly urban (90%) and highly concentrated: 46% live in the capital city and in the province of Buenos Aires. Of the total number, 20,593,330 are women (51%) and 48.5% of them are over 25 years old. The distribution of our cases with a predominance of those from both the city and the province of Buenos Aires (43, 4%) is similar to the population distribution according to the last census [7] , which indicates that the territorial distribution of breast cancer is mainly due to factors related to population density and not to other geographical variables.
Aging is the main risk factor for BC. Demographic changes in Latin America lead to an epidemiological transition, transforming the age structure of society into an ageing one. Today, 11,8% of Argentina's female population is above 65 years of age, being one of the oldest female populations in Latin America [7] .The presentation profile of BC in the series studied shows a predominant population of women over 55 years of age (median of 59). Uncommon below 30 years of age (1,1%), BC doubles the cases in 30-34 year-old women (2,1%), keeping up this increase rate in 35-39 year-old (5,3%) and 40-44 year-old (8,5%) age groups. Up until this age group, the increase of cases is almost constant, every five-year periods; afterwards, the trend tends to stabilize between the 45-49 and the 65-69 year-old age groups. Considering the age limit for systematic mammographic screening recommended [8, 9] we have observed that 8,5% of our BC cases appear in women under 40 and 18,7% more cases are added between 40 and 50 years of age. These percentages are not consistent with those outlined for developing countries, particularly those of Latin America, where there is predominance of young patients and with a proportion of women under 40 that varies between countries from 8,2% to 14%, our percentage (8,5%) being closer to lower values [10] . On the contrary, this profile is similar to that observed in developed countries [11] .
The country has a well-developed public health system that coexists with a social security system and a private sector; approximately 41% of the population lacks any form of health insurance so they are managed by the public health sector. The relationship between socioeconomic status and risk of BC is well established, with women with a higher socioeconomic background at also a higher risk. By contrast those cases in patients with lower socioeconomic background occur in more advanced stages [12] . This relationship is most likely indirectly related to lifestyle differences. In our study, the socioeconomic level was indirectly evaluated through education level and the health coverage system of the patient. 52, 2% of the patients had a high school or higher education diploma, 24% of them with complete university studies, while in the last 2010 census the percentage of women over 25 with that level of studies was 17.8%. In Argentina, a minimum benefit of health services is guaranteed by law to the whole population, so all BC patients have free access to oncology treatment. 79,1% of patients were covered either by the social security or by prepaid medical care. Both variables point to a woman of medium to high cultural and economic levels as described in populations of developed countries [13] .
The most known major risk factors for BC are environmental and mainly hormonal. The hypothesis that hormonal exposure that occurs between menarche and menopause and more recently in the time between menarche and age at first pregnancy is especially important in determining subsequent risk of BC is supported by several lines of evidence [14, 15] . Although the median age of menarche was 13 years of age and the highest percentage was in the group of 13 and 14, 43, 3 % of patients had menarche at 12 or younger. These values are consistent with other series [16] and indicative, to some extent, of a cohort of women with a relative early menarche onset.
It is known that women who undergo menopause before age 30 have a reduction in BC risk when compared with women who undergo menopause after age 55 [16, 17] Data from our study show a population of menopausal women (72.3%) with a median age of cessation of menses of 49 with a broad range between 21 and 64. The time of exposure to hormones, when calculated using the difference between the median age at menarche and menopause, shows a value of 36 years for the population under study. Median age between the age of the last menstruation and the age of onset of BC shows a difference of 10 years, 49 and 59 years respectively. Our finding of a dominant postmenopausal population does not match one debated theory about a higher incidence of premenopausal breast cancer in less developed countries [18] .
Only 9, 5% of patients had an HRT and most of them (69, 1%) for less than 5 years. This low rate of use and the short length of the treatment may be due to the well-known complications [19] that led to the contraindication of its use after the 2002 publication of the Women's Health Initiative randomized trial results [20] . It was at that time when this cohort of women with BC cancer went into menopause.
While low and delayed parity are known risk factors for the disease, lactation appears to play an important role in protecting women from BC [21] . There are changes in Argentinian women's lifestyles with a decline in the fertility rate. According to the last census, the average number of children was 2 and the average age at first birth was 24 years, both data similar to those observed in the patients in our series. A first full-term pregnancy before age 21 appears to have a protective effect against BC and in our series only 20, 9% of the patients were under that age at the time of first delivery. On the other hand, a late (over 30 years of age) first fullterm pregnancy (11, 6% of the patients) and null parity, 19,1% of our cases versus the 11% of the female population over 25 years old according to the last census [7] , may be associated with a higher risk [22] . None of these values are particularly high when compared with those mentioned in other publications [23, 24] .The use of oral contraceptives linked to increased risk of breast cancer [25] , was present in only in 37, 2 % cases and for no more than 3 years not being thus a significant risk factor in this series.
The existence of a history of interrupted pregnancies and the amount of these were considered, particularly in the past, as possible risk factors for breast cancer [26] . With only 28,9% of patients with this history and in most cases (84.6%) in not more than two occasions, these values do not appear to be significant and even less so if this is not currently considered a relevant risk factor [27] . The practice of breastfeeding and a longer duration of it are considered as protective factors of the mammary gland, thereby reducing the lifetime risk for developing a cancer. Although 100% of the parous women (1387) in this series reported having practiced breastfeeding, quite a high percentage if compared with other series [28] the average length of lactation -taking into account all of the patient's breastfed children -was only 6 months with a range between 0 and 24. This length of time would be insufficient to exert the debatable protective effect attributable to breastfeeding duration [28, 29] and it is within the shortest time recommended by medical organizations [30] .
For years the increase in BMI was related to the risk of developing BC primarily in postmenopausal women [31] . More than half of our patients were either overweight (39, 6%) or obese (18, 1%) at the time of diagnosis. These data on changes in BMI are relevant as risk factor because they come from a population of mainly menopausal patients (72, 3%) at the time of diagnosis of BC, as mentioned before.
The report of a history of a diagnosis of proliferative benign breast disease such as dysplasia, an entity with a low to moderate increased risk for the development of BC, was relative low (13,1% in this study), taking in account that it is more frequent in the general population [32] . Conditions such as atypical hyperplasia and carcinoma "in situ", both more closely related to the development of subsequent invasive cancer [33] , were reported in a low percentage (1, 7%). It should be noted that these records were collected by interrogation without histopathological confirmation. This could explain the observed differences with other series where the frequency is higher [34] . A more accurate history of personal BC is present in 9, 8% of cases, similar to the frequency observed in other series [35] . Family history of cancer reflects not only the consequences of genetic susceptibilities but also of shared environment and common culture. The percentage of family BC in our series (27, 9%) and its distribution according to degree of kinship is quite similar to that cited worldwide [36, 37] . A history of family non-breast cancer, although present in a high percentage of cases (23, 7%) in comparison with other series, shows no relevant data regarding types of cancers and frequencies thereof [38] .
The main morphological characteristics, like size and location, show a striking fact: a rate of 3% of bilateral cases at time of diagnosis (synchronous forms). This is a high value compared to past and current series [39] and strikingly it is almost double the figure recorded in a previous work done by us [40] . Histologically, infiltrative ductal carcinomas are the most common -76.3% of cases in this series-as noted throughout the literature [41, 42] while the percentage of infiltrative lobular carcinomas -11.4% in our series-is quite similar to that reported in literature -almost 10% [43] . As for "in situ" forms, ductal carcinoma in situ (DCIS) has become a more frequent form after the introduction of screening mammography, representing up to 20%-25% of all breast malignancies in industrialized countries [44] . This is not what happens in our series, where DCIS only represents 11.6% of all cases. On the other hand, lobular carcinoma in situ (LCIS) constitutes only 0.34% of the total when literature indicates a frequency in otherwise benign biopsy specimens ranging from 0.5% to 3.8% [45] . These low percentages in our study may be due to the fact that these forms increase their diagnostic frequency when the mammogram is applied in screening programs and not only in sporadic screening or for diagnostic purposes. This is the picture in the detection of breast cancer in our country, similar to that mentioned for other countries in the region [46] . For breast cancer, histologic grade remains a prognostic factor despite changes in tumor size and number of positive lymph nodes [47] ; it may be indirectly informative about tumor biology. With more than half the tumors (57%) with grades 1 and 2, tumors in this series appear to be biologically less aggressive.
According to an expert survey in Latin America, contrary to the relatively low or non-adherence to routine mammography screening, post-diagnostic screening with hormone receptors and biologic marker determination is widely spread in the region [48] . Thus, in our series the study of hormone receptors was performed in more than 86% of cases and of Her2-neu in over 80%. These rates of performance are among the highest according to the consulted bibliography [49] . The study of the proliferation index by the expression of ki-67 protein was performed in nearly 50% of cases. IHC expression of CK 5-6, used to differentiate luminal types A from B, was used in less than 2% of cases. Hormone receptors were studied by IHC in over 80% of cases, having in 1247 (82, 4%) of the total cases also the study of Her-2neu which allowed us to define molecular types. HR (+); Her2neu (-) is the most frequent and their percentage (close to 70%) is similar to most of the series analyzed [50] .In the remaining cases, subtype "triple-negative" (10%) prevails, followed by the "triple-positive" (7, 5%). These subtypes with a special prognostic/predictive significance are present in similar proportions to those mentioned in other populations studied and are consistent with the distribution in series with predominance of postmenopausal patients [49, 50] .
The stage at time of diagnosis affects the outcome and consequently the burden of the disease on societies. In our series, stages 0 and I take together correspond to 43, 9% of cases. This percentage is much higher than that mentioned for stage I in some series from Latin American countries, where the incidence ranges between 9% (Brazil, Peru and Mexico) and 40% (Uruguay). Conversely in this series only 2, 4% breast cancers were diagnosed with denovo distant metastases, at stage IV. This percentage is among the three lowest percentages reported in a total of 14 sets of breast cancer from countries in the region [51] . When comparing the stages of presentation in our series and those outlined in a series from a developed country like the United States [52] , it is observed that in the latter, stages 0 and I predominate while in our series stages II and III (48, 5%) are the most frequent. The prevalence of early stages in developed countries may be due to a massive and continuous use of mammogram screening in these populations. On the contrary, in our population, although the use of mammography is known and applied, it is not massive and systematic [48] . In stage IV our percentage (2.4%) is lower than that referred for more developed societies (6-7%) [53] .This situation may reflect the presence of more aggressive tumors that debut with metastatic stages or, perhaps more likely, that the techniques used for staging BC are of higher sensitivity and specificity in developed societies.
Conclusion
In summary, the profile of BC cases studied shows mostly a population of postmenopausal women averaging 60 years of age. Recognized risk factors related to reproduction (menarche, age at menopause, parity and lactation) are present with values similar to those described in Western populations in developed countries. Personal and/or family history of breast cancer and other non-breast cancer rates are similar to those observed in developed and Western populations. Regarding histological types and molecular profiles of tumors, no significant differences are observed when compared to other populations worldwide. Given all the previously mentioned variables, we have a population that shows a "western and developed" profile. This profile may describe a population with high incidence rates for the region, although these rates are lower than those in more developed Western countries for this type of cancer [1] .
It had been suggested that the geographic variation in BC incidence is due to differences between countries in known risk factors, especially reproductive ones [54, 55] . Nevertheless, hypotheses which postulate that the known reproductive risk factors cannot completely explain the geographic variation in BC incidence have been listed [56] [57] [58] . In our country, the influence of predominantly European immigration -an element of extreme importance in population composition during the last centuryon the genetic and cultural background of the population should be also considered [59] . We believe that classic demographic and clinic-pathological factors must be fully integrated with the results of the new and ever more numerous investigations on population genomic profiles [60] [61] [62] in order to explain the high incidence rates observed in our country as compared to those observed in the region and among other developing countries [63] [64] [65] .
